HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin protectant monograph

This article was originally published in The Rose Sheet

Executive Summary

FDA technical amendment to the Skin Protectant Drug Products Final Monograph corrects an incorrect "approved as of" date for ingredients published with the monograph last year (1"The Rose Sheet" June 9, 2003, p. 3). Final document had an incorrect "approved as of" date of May 7, 1991, rather than Nov. 10, 1993, FDA says in a Federal Register notice Aug. 18. Published monograph also inadvertently included select paragraphs in the wrong section, FDA adds...

You may also be interested in...



Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations

The Skin Protectant Final Monograph covering products for minor cuts, scrapes, burns, chapped skin and lips, poison ivy, poison oak, poison sumac and insect bites allows for certain cross-monograph ingredient combinations, according to the rule published in the 1Federal Register June 4

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

UsernamePublicRestriction

Register

RS012396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel